Company / SG&A Expense
Sarepta Therapeutics SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$491.7M
FY2025
5-year range
$282.7M / $557.9M
FY2021-FY2025
Trend
-11.9%
vs FY2024
Sector context
#38 of 213
Health Care
What the data says
Sarepta Therapeutics's sg&a expense of $492M is higher than 82% of companies in the Health Care sector (FY2025). SG&A Expense has fluctuated over the past 10 years, ranging from $84M in FY2016 to $558M in FY2024.
Based on SEC 10-K filings.
$492M in FY2025 with a 5-year CAGR of +18.8%. Top quartile in the Health Care sector.
Increased from $482M to $492M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.7%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 213This company $491.7M Sector average $722.3M
▼
-31.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 11.9% year-over-year.
- Ranks #38 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $491.7M | -11.9% |
| FY2024 | $557.9M | +15.8% |
| FY2023 | $481.9M | +51.6% |
| FY2022 | $317.9M | +12.5% |
| FY2021 | $282.7M | +36.1% |
| FY2020 | $207.8M | +69.3% |
| FY2019 | $122.7M | -41.0% |
| FY2018 | $207.8M | +69.3% |
| FY2017 | $122.7M | +46.5% |
| FY2016 | $83.7M | +11.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026